Skip to main content

Atrium Mesh Lawsuits: Monthly Status Conference on March 8

Atrium Mesh Lawsuits: Monthly Status Conference on March 8

Atrium Mesh Lawsuits: Monthly Status Conference on March 8

Introduction

The Atrium C-Qur Hernia Mesh lawsuits centralized in 2017 under MDL 2753 in the U.S. District Court for the District of New Hampshire include all types of C-Qur line of polypropylene surgical mesh. Hon. Judge Landya B. McCafferty is presiding over the Atrium Medical Corp. litigation where more than 20 lawsuits are pending for trial.

The court convened a regular monthly status conference on March 8 to discuss bellwether case management order, plaintiffs jurisdictional requests, deposition dates for plaintiffs’ requested Rule 30(b)(6) deponent, defendants’ privilege log, and location of the deposition of Reinhard Mayer primarily.

Plaintiffs allege that the C-Qur mesh causes an inflammatory response that may result in improper fixation, bowel adhesions, and other severe complications. Claims also include that Atrium failed to provide appropriate safety warnings to the medical community and patients in spite of being aware of the alleged design defects.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

First Federal Bellwether Trial Set in Strattice Mesh Case

Categories: Hernia Mesh

Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…

Tepezza Hearing Loss Trial Set for June 2026

Categories: Tepezza

The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.

This decision comes as attorneys…

FDA Moves to Restrict Dangerous 7-OH Opioid Products

Categories: Opioids

In a significant move to combat the ongoing opioid crisis, the U.S. Food and Drug Administration (FDA) has recommended a scheduling action under the Controlled Substances Act (CSA) to regulate certain products containing 7-hydroxymitragynine (7-…

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!